With a market capitalization (market cap) of $1.07B — a measure of how much the company is worth — Inhibrx Biosciences Inc. ranks #2,371 among the 2,418 companies tracked, and 342nd in Healthcare as of November 18, 2026. Shares trade at $72.44, down 2.35% on the day.
As of November 18, 2026 · Prices may be delayed
of 2,418 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series and can differ when the share count changes. Returns below show the total change over each period. Use the CAGR calculator to calculate an annualized return. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation November 13, 2026. The headline market cap is from the ranking update on November 18, 2026.
| Year | As of | Market cap | Annual change | Share-price close |
|---|---|---|---|---|
| 2026Latest available | Nov 13, 2026 | $1.31B | +6.36% | $83.30 |
| 2025 | Dec 31, 2025 | $1.23B | +416.87% | $79.00 |
| 2024 | Dec 31, 2024 | $238.21M | -88.40% | $15.40 |
| 2023 | Dec 29, 2023 | $2.05B | +92.60% | $38.00 |
Ranking figure $1.07B as of November 18, 2026.
Market cap = share price × shares outstanding.
Inhibrx Biosciences Inc.'s ranking market cap is the reported market cap from the latest ranking update, with a share price of $69.99 as of November 18, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.31B on November 13, 2026. See how the ranking works.
The ranking snapshot ($1.07B as of November 18, 2026) is FMP company-screener market cap. The historical observation ($1.31B on November 13, 2026) is FMP historical-market-capitalization for the same ticker. The live quote market cap agrees with the ranking snapshot. This page does not replace one series with the other.
Current shares outstanding are unavailable from the latest quote. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 15,487,000 shares. That figure is an average for the year, not the live count in the market-cap formula.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Quote as of . Prices may be delayed. Day figures refer to the quote's trading session.
Latest quote: $69.99. The headline price of $72.44 is from the ranking update on Nov 18, 2026. These updates can differ in timing.
Largest U.S.-listed companies in the same sector. These companies may serve different markets.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #11 | Eli Lilly and Company LLY | $1.31T | -1.68% |
| #19 | Johnson & Johnson JNJ | $664.04B | -1.00% |
| #23 |
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of November 18, 2026, Inhibrx Biosciences Inc. (INBX) is worth $1.07B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Inhibrx Biosciences Inc.’s book equity is about $7.99M. Market cap is the market value of the outstanding shares. As of November 18, 2026, its market cap is $1.07B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Inhibrx Biosciences Inc. ranks #2,371 among the 2,418 companies tracked on MarketCapLens. In Healthcare it ranks #342 of 353.
Financial figures are annual and labeled with their fiscal year (FY). Current-price P/E uses the latest available share price and annual earnings per share.
| 2022 | Dec 30, 2022 | $1.07B | -37.43% | $24.64 |
|---|
| 2021 | Dec 31, 2021 | $1.7B | — | $43.67 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
FY 2025
Return on equity data unavailable for FY 2025
FY 2025
Return on assets data unavailable for FY 2025
FY 2025
| $508.92B |
| -1.58% |
| #31 | Merck & Co., Inc. MRK | $342.3B | -3.09% |
| #35 | UnitedHealth Group Incorporated UNH | $318.26B | -8.69% |
| #38 | Novartis AG NVS | $294.55B | -1.99% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2368 | Gold.com, Inc. GOLD | $1.07B | +3.89% |
| #2369 | Northeast Bank NBN | $1.07B | +1.66% |
| #2370 | Sinclair, Inc. SBGI | $1.07B | +2.03% |
| #2372 | Oaktree Specialty Lending Corporation OCSL | $1.06B | +2.32% |
| #2373 | Omeros Corporation OMER | $1.06B | +2.23% |
| #2374 | Five Star Bancorp FSBC | $1.06B | -0.01% |
Inhibrx Biosciences Inc.’s ranking market cap of $1.07B comes from the same snapshot as the rest of this site, as of November 18, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 15,487,000. The ranking snapshot ($1.07B as of November 18, 2026) is FMP company-screener market cap. The historical observation ($1.31B on November 13, 2026) is FMP historical-market-capitalization for the same ticker. The live quote market cap agrees with the ranking snapshot. This page does not replace one series with the other.
Over the past year, Inhibrx Biosciences Inc.’s market cap is up 13.31%, using historical market-cap records rather than today’s share count applied to past prices.
Inhibrx Biosciences Inc. (INBX) shares trade at $72.44, down 2.35% on the day, as of November 18, 2026.
Live P/E is share price divided by annual earnings per share. It is blank when earnings are missing, zero, or negative — not a 0× multiple.